Incannex reported it has approximately USD 75 million in cash and no debt following the completion of a financing. The company said its market capitalization is approximately USD 46 million at current trading levels. Incannex said proceeds from the financing are expected to fund its DReAMzz Phase 2 crossover dose-optimization study for IHL-42X.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603180800PRIMZONEFULLFEED9674246) on March 18, 2026, and is solely responsible for the information contained therein.
Comments